New Concepts in the Treatment of Rheumatoid Arthritis

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 197-216

  Goldbach Mansky, Raphaela ^a   Lipsky, Peter E ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Anti cytokine therapy; Combination therapy; DMARDs; Early aggressive treatment; Outcome; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE ANTIBODY; ETANERCEPT; FOLIC ACID ANTAGONIST; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; SULFONAMIDE; TUMOR NECROSIS FACTOR ANTIBODY; CYTOKINE;

ANOREXIA; APLASTIC ANEMIA; APPETITE DISORDER; ARTHROPATHY; BONE MARROW SUPPRESSION; CANCER; CATARACT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DECISION MAKING; DEMYELINATING DISEASE; DEMYELINATION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DOSE TIME EFFECT RELATION; EARLY DIAGNOSIS; EXTRAPULMONARY TUBERCULOSIS; HAIR LOSS; HIRSUTISM; HUMAN; HYPERPIGMENTATION; HYPERTENSION; IMMUNOTHERAPY; INFECTION; INSULIN RESISTANCE; LIVER TOXICITY; LUNG TOXICITY; LUNG TUBERCULOSIS; MOUTH ULCER; NAUSEA; NEUROPATHY; OSTEOPOROSIS; PATHOGENESIS; PHOTOSENSITIVITY DISORDER; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SYMPTOMATOLOGY; TREMOR; CLINICAL TRIAL; DISEASE COURSE; DRUG ANTAGONISM; DRUG COMBINATION; FOLLOW UP; IMMUNOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYTOKINES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS;

EID: 0000415293     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152342     Document Type: Review

References (108)

1. Pincus T. 1995. Long-term outcomes in rheumatoid arthritis. Br. J. Rheumatol. 34(Suppl. 2):59-73
2. Albani S, Carson D. 1997. Etiology and pathogenesis of rheumatoid arthritis. In Arthritis and Allied Conditions: A Textbook of Rheumatology, ed. WJ Koopman, 51:979-92. Baltimore, MD: Williams & Wilkins
3. Young A, Dixey J, Kulinskaya E, et al. 2002. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann.Rheum. Dis. 61:335-40
4. Yelin E, Wanke LA. 1999. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42:1209-18
5. Scott DL. 2000. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl. 1):24-29
6. Fuchs HA, Kaye JJ, Callahan LF, et al. 1989. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J. Rheumatol. 16:585-91
7. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. 1992. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 35:26-34
8. Wolfe F, Sharp JT. 1998. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 41:1571-82
9. Gordon P, West J, Jones H, Gibson T. 2001. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J. Rheumatol. 28:2409-15
10. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B. 2000. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst. Rev. CD002048
11. Suarez-Almazor ME, Spooner C, Belseck E. 2000. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD001461
12. Suarez-Almazor ME, Belseck E, Shea B, et al. 2000. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD001157
13. Suarez-Almazor ME, Spooner C, Belseck E. 2000. Penicillamine for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD001460
14. Felson DT, Anderson JJ, Meenan RF. 1992. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 35:1117-25
15. Weinblatt ME, Coblyn JS, Fox DA, et al. 1985. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312:818-22
16. Williams HJ, Willkens RF, Samuelson CO Jr, et al. 1985. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 28:721-30
17. Suarez-Almazor ME, Belseck E, Shea B, et al. 2000. Methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. CD000957
18. Weinblatt ME, Reda D, Henderson W, et al. 1999. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol. 26: 2123-30
19. Suarez-Almazor ME, Belseck E, Shea B, et al. 2000. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst. Rev. CD000959
20. Tilley BC, Alarcon GS, Heyse SP, et al. 1995. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann. Intern. Med. 122:81-89
21. O'Dell JR, Haire CE, Palmer W, et al. 1997. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 40:842-48
22. Wells G, Haguenauer D, Shea B, et al. 2000. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst. Rev. CD001083
23. Criswell LA, Saag KG, Sems KM, et al. 2000. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst. Rev. CD001158
24. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. 2002. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. 136:1-12
25. Clark P, Tugwell P, Bennet K, et al. 2000. Injectable gold for rheumatoid arthritis. Cochrane Database Syst. Rev. CD000520
26. Hewitson PJ, Debroe S, McBride A, Milne R. 2000. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J. Clin. Pharm. Ther. 25:295-302
27. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. 1996. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 39:723-31
28. Ortiz Z, Shea B, Suarez-Almazor ME, et al. 1998. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J. Rheumatol. 25:36-43
29. Scott DL, Shipley M, Dawson A, et al. 1998. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br. J. Rheumatol. 37:546-54
30. Kremer JM, Phelps CT. 1992. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 35:138-45
31. Tishler M, Caspi D, Yaron M. 1993. Long-term experience with low dose methotrexate in rheumatoid arthritis. Rheumatol. Int. 13:103-6
32. Weinblatt ME, Weissman BN, Holdsworth DE, et al. 1992. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 35:129-37
33. van Riel PL, van der Heijde DM, Nuver-Zwart IH, van de Putte LB. 1995. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J. Rheumatol. 22:1797-99
34. Alarcon GS, Bartolucci AA. 2000. Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline. J. Rheumatol. 27:530-34
35. Gough AK, Lilley J, Eyre S, et al. 1994. Generalized bone loss in patients with early rheumatoid arthritis. Lancet 344:23-27
36. Keller C, Hafstrom I, Svensson B. 2001. Bone mineral density in women and men with early rheumatoid arthritis. Scand. J. Rheumatol. 30:213-20
37. Barrett EM, Scott DG, Wiles NJ, Symmons DP. 2000. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 39:1403-9
38. Merkesdal S, Ruof J, Schoffski O, et al. 2001. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44:528-34
39. Eberhardt K, Fex E. 1998. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br. J. Rheumatol. 37:1324-29
40. Harrison BJ, Symmons DP, Brennan P, et al. 1996. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br. J. Rheumatol. 35:1096-100
41. Chan KW, Felson DT, Yood RA, Walker AM. 1994. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum. 37:814-20
42. Yelin EH, Such CL, Criswell LA, Epstein WV. 1998. Outcomes for persons with rheumatoid arthritis with arheumatologist versus a non-rheumatologist as the main physician for this condition. Med. Care 36:513-22
43. Saraux A, Berthelot JM, Chales G, et al. 2001. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum. 44:2485-91
44. Kaarela K, Kauppi MJ, Lehtinen KE. 1995. The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand. J. Rheumatol. 24:279-81
45. Brennan P, Harrison B, Barrett E, et al. 1996. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 313:471-76
46. Combe B, Dougados M, Goupille P, et al. 2001. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 44:1736-43
47. Gough A, Faint J, Salmon M, et al. 1994. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum. 37:1166-70
48. Mottonen T, Paimela L, Leirisalo-Repo M, et al. 1998. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann. Rheum. Dis. 57:533-39
49. van der Heijde DM, van Riel PL, van Leeuwen MA, et al. 1992. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br. J. Rheumatol. 31:519-25
50. van der Heide A, Remme CA, Hofman DM, et al. 1995. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum. 38:1466-74
51. van Zeben D, Hazes JM, Zwinderman AH, et al. 1993. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J. Rheumatol. 20:1288-96
52. Young A, Bielawska C, Corbett M, Roitt I. 1987. A prospective study of early onset rheumatoid arthritis over fifteen years: prognostic features and outcome. Clin. Rheumatol. 6(Suppl. 2):12-19
53. Visser H, le Cessie S, Vos K, et al. 2002. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 46:357-65
54. van Leeuwen MA, Westra J, van Riel PL, et al. 1995. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand. J. Rheumatol. 24:146-53
55. Feigenbaum SL, Masi AT, Kaplan SB. 1979. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am. J. Med. 66:377-84
56. van der Horst-Bruinsma IE, Speyer I, Visser H, et al. 1998. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br. J. Rheumatol. 37:1084-88
57. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. 1994. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21:425-29
58. Mottonen T, Paimela L, Ahonen J, et al. 1996. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum. 39:996-1005
59. van Zeben D, Breedveld FC. 1996. Prognostic factors in rheumatoid arthritis. J. Rheumatol. Suppl. 44:31-33
60. Harrison BJ, Symmons DP, Brennan P, et al. 1996. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J. Rheumatol. 23: 1326-31
61. Borg G, Allander E, Berg E, et al. 1991. Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial. J. Rheumatol. 18:1015-20
62. Davis MJ, Dawes PT, Fowler PD, et al. 1991. Should disease-modifying agents be used in mild rheumatoid arthritis? Br. J. Rheumatol. 30:451-54
63. Australian Multicentre Clinical Trial Group. 1992. Sulfasalazine in early rheumatoid arthritis. J. Rheumatol. 19:1672-77
64. Hannonen P, Mottonen T, Hakola M, Oka M. 1993. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 36:1501-9
65. HERA Study Group. 1995. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am. J. Med. 98:156-68
66. van der Heide A, Jacobs JW, Bijlsma JW, et al. 1996. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124:699-707
67. Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. 1993. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J. Rheumatol. 20:243-47
68. Egsmose C, Lund B, Borg G, et al. 1995. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J. Rheumatol. 22:2208-13
69. Anderson JJ, Wells G, Verhoeven AC, Felson DT. 2000. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum. 43:22-29
70. Munro R, Hampson R, McEntegart A, et al. 1998. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann. Rheum. Dis. 57:88-93
71. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. 2000. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J. Rheumatol. 27:623-29
72. Landewe RB, Boers M, Verhoeven AC, et al. 2002. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46:347-56
73. Quinn MA, Conaghan PG, Emery P. 2001. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology (Oxford) 40:1211-20
74. Fries JF, Williams CA, Ramey D, Bloch DA. 1993. The relative toxicity of disease modifying antirheumatic drugs. Arthritis Rheum. 36:297-306
75. Lard LR, Boers M, Verhoeven A, et al. 2002. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum. 46:899-905
76. Gabriel SE, Crowson CS, O'Fallon WM. 1999. Mortality in rheumatoid arthritis: Have we made an impact in 4 decades? J. Rheumatol. 26:2529-33
77. Pincus T, Callahan LF. 1986. Taking mortality in rheumatoid arthritis seriously -predictive markers, socioeconomic status and comorbidity. J. Rheumatol. 13:841-45
78. Choi HK, Hernan MA, Seeger JD, et al. 2002. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173-77
79. Symmons DP, Jones MA, Scott DL, Prior P. 1998. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J. Rheumatol. 25:1072-77
80. Kroot EJ, Van Leeuwen MA, Van Rijswijk MH, et al. 2000. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann. Rheum. Dis. 59:954-58
81. Boers M, Verhoeven AC, Markusse HM, et al. 1997. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309-18
82. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. 1997. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br. J. Rheumatol. 36:1082-88
83. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. 1999. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353:1568-73
84. Dougados M, Combe B, Cantagrel A, et al. 1999. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58:220-25
85. Proudman SM, Conaghan PG, Richardson C, et al. 2000. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum. 43: 1809-19
86. Tugwell P, Pincus T, Yocum D, et al. 1995. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333:137-41
87. O'Dell JR, Haire CE, Erikson N, et al. 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334:1287-91
88. Kremer JM, Alarcon GS, Caldwell JR, et al. 2000. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone. Arthritis Rheum. 43(9):S224 (Abstr.)
89. O'Dell JR, Leff R, Paulsen G, et al. 2002. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:1164-70
90. Mottonen T, Hannonen P, Korpela M, et al. 2002. Delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 46:894-98
91. Green M, Marzo-Ortega H, McGonagle D, et al. 1999. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum. 42:2184-88
92. Kirwan JR. 1995. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. 333:142-46
93. Rau R. 2001. Low dose steroid therapy in rheumatoid arthritis: a model for therapy of inflammatory diseases? Results of the LDPT Study. Z. Rheumatol. 60:111-12
94. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. 2001. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 44:1496-503
95. Maini RN, Taylor PC. 2000. Anticytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51:207-29
96. Moreland LW, Schiff MH, Baumgartner SW, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130:478-86
97. Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552-63
98. Bathon JM, Martin RW, Fleischmann RM, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:1586-93
99. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196-204
100. Weinblatt ME, Kremer JM, Bankhurst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253-59
101. Lipsky PE, van der Heijde DM, St Clair EW, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343:1594-602
102. Cohen S, Hurd E, Cush J, et al. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:614-24
103. Moreland LW, Cohen SB, Baumgartner SW, et al. 2001. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 28: 1238-44
104. Arthritis Drugs FDA Advisory Committee. 2001. Safety update on TNF-α antagonists: infliximab and etanercept. 1st ed. http://www.fda.gov/ ohrms/dockets/ac/ 01/briefing/3779b2.htm
105. Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44:2862-69
106. Schiff MH, Bulpitt K, Weaver AA, et al. 2001. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum. 44(9):S79 (Abstr.)
107. Moreland LW, Alten R, van den Bosch F, et al. 2002. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4tg and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46(6): 1470-79
108. Choy EH, Isenberg DA, Farrow S, et al. 2001. A double-blind, randomized, placebo-controlled trial of anti-interleukin-6 (IL-6) receptor monoclonal antibody in rheumatoid arthritis (RA). Arthritis Rheum. 44(9):5274 (Abstr.)